Chicago, IL – December 21, 2017– Brown Gibbons Lang & Company (BGL) is pleased to announce that it served as financial advisor to Quantum Pharma plc (AIM:QP.), a leading UK supplier of specials and unlicensed medicines, on its sale to Clinigen Group plc (AIM:CLIN), a global pharmaceutical services company. The transaction was led by BGL’s Healthcare and Life Sciences Group.
N+1 Singer Advisory LLP acted as financial advisor for the purposes of Rule 3 of the Takeover Code, nominated advisor, and broker to Quantum. Muckle LLP served as Quantum’s legal advisor, and Buchanan acted as the Group’s Financial PR and Investor Relations advisor.
The transaction, effected by the means of a Scheme of Arrangement, was recommended by Quantum’s board on September 13, 2017. The Scheme of Arrangement was published on September 29, 2017, and ultimately became effective November 1, 2017. The acquisition valued each Quantum share at approximately 82 pence, and Quantum’s fully diluted share capital at approximately £157.8 million in total enterprise value.
The acquisition will accelerate Clinigen’s strategic initiative to become the global leader in the supply of unlicensed medicines. Moreover, Quantum’s pipeline of unlicensed to licensed specials and niche generics bolsters Clinigen’s existing pipeline, and increases Clinigen’s ability to convert unlicensed medicines into licensed products, bridging the gap between Clinigen’s unlicensed medicines and commercial medicines divisions. Geographically, Clinigen’s global footprint and distribution provide immediate opportunities for Quantum’s licensed products, especially in Asia-Pacific and Africa.
“The Quantum board believes the strategic fit of the two groups is strong,” commented Quantum CEO Chris Rigg. “As part of the Clinigen Group, Quantum will be able to drive faster strategic growth and gain immediate access to international markets that will complement our existing product portfolio, provide additional routes to market for our development pipeline and accelerate the Group’s strategic plan.”
Quantum Pharma is a service led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler and hospital markets. Quantum operates through two divisions – Specials and Niche Pharmaceuticals – offering a portfolio of innovative and complementary products and services and incorporating seven primary business units across six sites in the UK and mainland Europe. Specials comprises five primary business units which primarily manufacture, procure and supply unlicensed medicines (Specials) and special obtains. Niche Pharmaceuticals comprises two business units which develop and commercialize niche pharmaceuticals.
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.